Bedaquiline: Difference between revisions

Latest revision as of 23:20, 17 February 2020

Antituberculosis antibiotic used as second-line therapy
Inhibits the ATP synthase proton pump in mycobacteria
Member of the diarylquinoline class of antibiotics
Adverse events include QTc prolongation, hepatitis, and possibly an increased risk of death
- Others: arthralgias, dizziness, headache, hyperuremia, insomnia, myalgia, nausea, prolonged QTc, pruritus, and vomiting

@@ Line 2: / Line 2: @@
 * Inhibits the ATP synthase proton pump in mycobacteria
 * Member of the diarylquinoline class of antibiotics
-* Adverse events include QT prolongation, hepatitis, and possibly an increased risk of death
+* Adverse events include [[Adverse drug reaction::QTc prolongation]], [[Adverse drug reaction::hepatitis]], and possibly an increased risk of death
+** Others: [[Adverse drug reaction::arthralgias]], [[Adverse drug reaction::dizziness]], [[Adverse drug reaction::headache]], [[Adverse drug reaction::hyperuremia]], [[Adverse drug reaction::insomnia]], [[Adverse drug reaction::myalgia]], [[Adverse drug reaction::nausea]], [[Adverse drug reaction::prolonged QTc]], [[Adverse drug reaction::pruritus]], and [[Adverse drug reaction::vomiting]]
 [[Category:Antibiotics]]